Merck Serono to pay $44 million to resolve US Rebif kickback claims
This article was originally published in Scrip
Executive Summary
Merck Serono has agreed to pay $44.3 million to resolve kickback allegations in connection with the marketing of the multiple sclerosis drug Rebif, according to the US Justice Department.